# Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

> **NCT06866262** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 55 (estimated)

## Conditions studied

- Locally Advanced Clear Cell Renal Cell Carcinoma
- Locally Advanced Sarcomatoid Renal Cell Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Sarcomatoid Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DIETARY_SUPPLEMENT:** Inulin
- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06866262
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2031-08-01
- **Final completion:** 2031-08-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06866262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06866262, "Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06866262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*